251 related articles for article (PubMed ID: 29217104)
1. [Does tocilizumab mean the end of glucocorticoids in giant cell arteritis?].
Samson M; Bonnotte B
Rev Med Interne; 2018 Feb; 39(2):75-77. PubMed ID: 29217104
[No Abstract] [Full Text] [Related]
2. [Efficacy and tolerance of tocilizumab for corticosteroid sparing in giant cell arteritis and aortitis: Experience of Nimes University Hospital about eleven patients].
Broner J; Arnaud E
Rev Med Interne; 2018 Feb; 39(2):78-83. PubMed ID: 29221884
[TBL] [Abstract][Full Text] [Related]
3. [From pathogenesis of giant cell arteritis to new therapeutic targets].
Samson M; Bonnotte B
Rev Med Interne; 2017 Oct; 38(10):670-678. PubMed ID: 28800947
[TBL] [Abstract][Full Text] [Related]
4. Giant cell arteritis with ocular involvement successfully treated with tocilizumab and very short-course glucocorticoids: A case report.
Khanna RK; Hage R; Lecler A; Sene T; Vignal-Clermont C; Clavel-Refregiers G
J Fr Ophtalmol; 2021 Apr; 44(4):481-484. PubMed ID: 33712335
[TBL] [Abstract][Full Text] [Related]
5. The long-term use of tocilizumab in giant cell arteritis.
Coath FL; Mukhtyar C
Rheumatology (Oxford); 2021 Oct; 60(10):4447-4449. PubMed ID: 33956087
[No Abstract] [Full Text] [Related]
6. [Clinical and biological efficacy of tocilizumab in giant cell arteritis: report of three patients and literature review].
Kieffer P; Hinschberger O; Ciobanu E; Jaeger-Bizet F; Drabo A; Mostoufizadeh T; Martzolff L
Rev Med Interne; 2014 Jan; 35(1):56-9. PubMed ID: 24075627
[TBL] [Abstract][Full Text] [Related]
7. Tocilizumab and glucocorticoids for giant cell arteritis: the learning curve.
Mackie SL; Bhogal R
Lancet Rheumatol; 2023 Dec; 5(12):e703-e705. PubMed ID: 38251559
[No Abstract] [Full Text] [Related]
8. [How long should treatment with tocilizumab be carried out for giant cell arteritis and how should it be ended (discontinue/taper off)?].
Henes J
Z Rheumatol; 2021 Mar; 80(2):176-179. PubMed ID: 33351160
[TBL] [Abstract][Full Text] [Related]
9. Giant cell arteritis: An updated review of an old disease.
Rinden T; Miller E; Nasr R
Cleve Clin J Med; 2019 Jul; 86(7):465-472. PubMed ID: 31291180
[TBL] [Abstract][Full Text] [Related]
10. Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients.
Régent A; Redeker S; Deroux A; Kieffer P; Ly KH; Dougados M; Liozon E; Larroche C; Guillevin L; Bouillet L; Espitia O; Costedoat-Chalumeau N; Soubrier M; Brihaye B; Lifermann F; Lefevre G; Puéchal X; Mouthon L; Toussirot E;
J Rheumatol; 2016 Aug; 43(8):1547-52. PubMed ID: 27182063
[TBL] [Abstract][Full Text] [Related]
11. Trial of Tocilizumab in Giant-Cell Arteritis.
Stone JH; Tuckwell K; Dimonaco S; Klearman M; Aringer M; Blockmans D; Brouwer E; Cid MC; Dasgupta B; Rech J; Salvarani C; Schett G; Schulze-Koops H; Spiera R; Unizony SH; Collinson N
N Engl J Med; 2017 Jul; 377(4):317-328. PubMed ID: 28745999
[TBL] [Abstract][Full Text] [Related]
12. Refractory giant cell arteritis on prednisone and tocilizumab: improvement with subsequent tuberculosis reactivation.
Kherani I; Chin C; Kherani RB; Kherani F
Can J Ophthalmol; 2019 Aug; 54(4):e192-e194. PubMed ID: 31358167
[No Abstract] [Full Text] [Related]
13. Giant cell arteritis: new concepts, treatments and the unmet need that remains.
Coath F; Gillbert K; Griffiths B; Hall F; Kay L; Lanyon P; Luqmani R; Mackie SL; Mason JC; Mills J; Mollan S; Morgan AW; Mukhtyar C; Quick V; Watts R; Dasgupta B
Rheumatology (Oxford); 2019 Jul; 58(7):1123-1125. PubMed ID: 30423174
[No Abstract] [Full Text] [Related]
14. Tocilizumab (Actemra) for giant cell arteritis.
Med Lett Drugs Ther; 2017 Sep; 59(1530):161-162. PubMed ID: 28922343
[No Abstract] [Full Text] [Related]
15. Immunosuppressive treatment for giant cell arteritis: where do we stand?
Pipitone N; Salvarani C
Clin Exp Rheumatol; 2015; 33(2 Suppl 89):S-5-6. PubMed ID: 26016749
[No Abstract] [Full Text] [Related]
16. Progression of large-vessel giant cell arteritis despite tocilizumab treatment.
Elfishawi M; Kaymakci M; Koster MJ; Warrington KJ
Clin Exp Rheumatol; 2023 Apr; 41(4):985-986. PubMed ID: 35930482
[No Abstract] [Full Text] [Related]
17. Tocilizumab for giant cell arteritis: what is optimal?
Kaymakci M; Warrington KJ
Clin Exp Rheumatol; 2023 Apr; 41(4):777-779. PubMed ID: 36995336
[No Abstract] [Full Text] [Related]
18. The Treatment of Giant Cell Arteritis in Different Clinical Settings.
Pfeil A; Oelzner P; Hellmann P
Front Immunol; 2018; 9():3129. PubMed ID: 30733723
[TBL] [Abstract][Full Text] [Related]
19. Tocilizumab in Giant Cell Arteritis.
Mariano VJ; Frishman WH
Cardiol Rev; 2018; 26(6):321-330. PubMed ID: 29570475
[TBL] [Abstract][Full Text] [Related]
20. Tocilizumab in Giant Cell Arteritis: Better Understanding the Benefits.
Buttgereit F; Palmowski A; Esen I; Brouwer E
Arthritis Rheumatol; 2023 Apr; 75(4):489-492. PubMed ID: 36468520
[No Abstract] [Full Text] [Related]
[Next] [New Search]
